Dr. Reddy’s Labs rolls out Carmustine for Injection, USP in US

Dr. Reddy’s Laboratories (Dr. Reddy’s Labs), an Indian pharma company, has launched Carmustine for Injection, USP in the US in the form of a lyophilized powder.

Carmustine for Injection, USP is approved by the US Food and Drug Administration (FDA) as a therapeutic equivalent generic version of BiCNU (carmustine for injection).

BiCNU is owned by Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals.

According to Dr. Reddy’s Laboratories, its generic version of BiCNU has been launched as a package which comprises a single-dose vial filled with 100 mg Carmustine USP and a vial having 3 mL sterile diluent.

Dr. Reddy’s Laboratories rolls out Carmustine for Injection, USP in US. Photo courtesy of Karthikndr/Wikimedia Commons.

Carmustine for injection used as palliative therapy as a single agent or in combination regimen with other approved chemotherapeutic agents in the treatment of various types of cancers and tumors.

As per IQVIA Health, the BiCNU brand and generic market had sales of around $19.4 million moving annual total (MAT) in the US for the most recent 12 months ending in August 2021.